Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

被引：0
|
作者：
Cortes, J
Plunkett, WK
Estey, EH
Keating, MJ
Madden, T
Sampath, D
Faderl, S
Beran, M
Dancey, J
Kantarjian, HM
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, CTEP, Bethesda, MD 20892 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4555
引用
收藏
页码：211B / 211B
页数：1
相关论文
共 50 条
  • [1] Pilot trial of Mylotarg, Topotecan and Ara-C in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Alvarez, RH
    Estey, EH
    Kantarjian, HM
    Giles, FJ
    Beran, M
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 340A - 341A
  • [2] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Gojo, Ivana
    Perl, Alexander
    Luger, Selina
    Baer, Maria R.
    Norsworthy, Kelly J.
    Bauer, Kenneth S.
    Tidwell, Michael
    Fleckinger, Stephanie
    Carroll, Martin
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1217 - 1227
  • [3] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Ivana Gojo
    Alexander Perl
    Selina Luger
    Maria R. Baer
    Kelly J. Norsworthy
    Kenneth S. Bauer
    Michael Tidwell
    Stephanie Fleckinger
    Martin Carroll
    Edward A. Sausville
    Investigational New Drugs, 2013, 31 : 1217 - 1227
  • [4] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 501A - 501A
  • [5] Phase 1 Study of UCN-01 in Combination with Perifosine in Patients with Relapsed and Refractory Acute Leukemias and High Risk Myelodysplastic Syndromes (MDS)
    Norsworthy, Kelly J.
    Perl, Alexander E.
    Carroll, Martin
    Luger, Selina M.
    Bauer, Kenneth S.
    Tidwell, Michael L.
    Ioffe, Dina
    Baer, Maria R.
    Sausville, Edward A.
    Goio, Ivana
    BLOOD, 2011, 118 (21) : 677 - 677
  • [6] Phase I study of Triapine® and cytarabine (ara-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS).
    Yee, KWL
    Cortes, J
    Garcia-Manero, G
    Verstovsek, S
    Ferrajoli, A
    Wierda, WG
    Thomas, D
    Faderl, S
    King, I
    O'Brien, SM
    Sznol, M
    Giles, FJ
    BLOOD, 2005, 106 (11) : 311B - 311B
  • [7] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2012, 120 (21)
  • [8] Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Cortes, Jorge E.
    Faderl, Stefan
    Pagel, John
    Jung, Chul Won
    Yoon, Sung-Soo
    Koh, Youngil
    Pardanani, Animesh Dev
    Hauptschein, Robert S.
    Lee, Kyoung-June
    Lee, Je-Hwan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    BLOOD, 2010, 116 (21) : 1214 - 1214
  • [10] Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents
    Navada, S. C.
    Odchimar-Reissig, R.
    Reddy, E. P.
    Demakos, E. P.
    Holland, J. F.
    Wilhelm, F.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2013, 37 : S146 - S146
12345